Sonoma Pharmaceuticals, Inc. (SNOA) 10-Year Financial Performance & Capital Metrics

SNOA • • Industrial / General

HealthcareSpecialty & Generic PharmaMedical Devices & Drug DeliveryDrug Delivery Systems

AboutSonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.Show more

Revenue $14M +12.2%
EBITDA -$4M +21.1%
Net Income -$3M +28.5%
EPS (Diluted) -2.79 +47.6%
Gross Margin 38.25% +2.7%
EBITDA Margin -25% +29.6%
Operating Margin -25.97% +29.7%
Net Margin -24.2% +36.3%
ROE -65.55% +4.3%
ROIC -188.07% -130.0%
Debt/Equity 0.07 -30.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.9x book value
✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 36.5% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y0.31%

5Y-4.44%

3Y4.2%

TTM25.02%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM5.62%

EPS CAGR

10Y-

5Y-

3Y-

TTM52.15%

ROCE

10Y Avg-63.36%

5Y Avg-38.83%

3Y Avg-37.24%

Latest-35.99%

Peer Comparison

Drug Delivery Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
EMBCEmbecta Corp.	746.07M	12.60	7.78	-3.8%	8.77%		24.45%
SNOASonoma Pharmaceuticals, Inc.	5.56M	3.27	-1.17	12.19%	-20.54%	-91.87%		0.07
GELSGelteq Limited Ordinary Shares	13.28M	1.24		-100%	-27.42%	-26.77%		0.25

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	9.37M	12.82M	16.66M	18.97M	17.93M	18.63M	12.63M	13.27M	12.73M	14.29M
Revenue Growth %	-0.32%	0.37%	0.3%	0.14%	-0.05%	0.04%	-0.32%	0.05%	-0.04%	0.12%
Cost of Goods Sold+	6.72M	7.16M	9.35M	10.09M	9.81M	12.07M	8.63M	8.79M	7.99M	8.82M
COGS % of Revenue	0.72%	0.56%	0.56%	0.53%	0.55%	0.65%	0.68%	0.66%	0.63%	0.62%
Gross Profit+	2.65M	5.67M	7.31M	8.88M	8.12M	6.56M	3.99M	4.48M	4.75M	5.46M
Gross Margin %	0.28%	0.44%	0.44%	0.47%	0.45%	0.35%	0.32%	0.34%	0.37%	0.38%
Gross Profit Growth %	-0.64%	1.14%	0.29%	0.21%	-0.09%	-0.19%	-0.39%	0.12%	0.06%	0.15%
Operating Expenses+	17.36M	18.64M	21.5M	20.14M	15.51M	10.01M	9.88M	9.05M	9.45M	9.18M
OpEx % of Revenue	1.85%	1.45%	1.29%	1.06%	0.87%	0.54%	0.78%	0.68%	0.74%	0.64%
Selling, General & Admin	15.56M	17.07M	19.92M	18.62M	14.17M	9.45M	9.76M	8.84M	7.58M	7.36M
SG&A % of Revenue	1.66%	1.33%	1.2%	0.98%	0.79%	0.51%	0.77%	0.67%	0.59%	0.52%
Research & Development	1.81M	1.58M	1.57M	1.52M	1.34M	555K	125K	207K	1.87M	1.81M
R&D % of Revenue	0.19%	0.12%	0.09%	0.08%	0.07%	0.03%	0.01%	0.02%	0.15%	0.13%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-14.71M	-12.97M	-14.19M	-11.26M	-7.39M	-3.45M	-5.89M	-4.57M	-4.7M	-3.71M
Operating Margin %	-1.57%	-1.01%	-0.85%	-0.59%	-0.41%	-0.19%	-0.47%	-0.34%	-0.37%	-0.26%
Operating Income Growth %	-1.21%	0.12%	-0.09%	0.21%	0.34%	0.53%	-0.71%	0.22%	-0.03%	0.21%
EBITDA+	-14.47M	-12.73M	-13.7M	-10.8M	-7.08M	-3.22M	-5.7M	-4.45M	-4.53M	-3.57M
EBITDA Margin %	-1.54%	-0.99%	-0.82%	-0.57%	-0.39%	-0.17%	-0.45%	-0.33%	-0.36%	-0.25%
EBITDA Growth %	-1.26%	0.12%	-0.08%	0.21%	0.34%	0.54%	-0.77%	0.22%	-0.02%	0.21%
D&A (Non-Cash Add-back)	244K	248K	490K	453K	312K	227K	186K	125K	176K	138K
EBIT	-14.72M	-12.93M	-14.24M	-11.31M	-3.53M	-3.45M	-5.89M	-4.57M	-4.7M	-3.71M
Net Interest Income+	-1K	19K	218K	157K	34K	4K	-10K	16K	0	0
Interest Income	2K	22K	258K	190K	50K	16K	0	16K	0	0
Interest Expense	3K	3K	40K	33K	16K	12K	10K	0	0	0
Other Income/Expense	-10K	37K	-89K	-82K	3.85M	-453K	469K	-614K	-330K	803K
Pretax Income+	-14.72M	-12.94M	-14.28M	-11.34M	-3.54M	-3.9M	-5.42M	-5.18M	-5.03M	-2.91M
Pretax Margin %	-1.57%	-1.01%	-0.86%	-0.6%	-0.2%	-0.21%	-0.43%	-0.39%	-0.4%	-0.2%
Income Tax+	0	-4.27M	50K	458K	29K	713K	-332K	-33K	-196K	550K
Effective Tax Rate %	0.69%	-0.72%	1%	1.04%	0.93%	1.01%	0.94%	0.99%	0.96%	1.19%
Net Income+	-10.16M	9.27M	-14.33M	-11.8M	-3.31M	-3.95M	-5.09M	-5.15M	-4.83M	-3.46M
Net Margin %	-1.08%	0.72%	-0.86%	-0.62%	-0.18%	-0.21%	-0.4%	-0.39%	-0.38%	-0.24%
Net Income Growth %	-0.24%	1.91%	-2.54%	0.18%	0.72%	-0.19%	-0.29%	-0.01%	0.06%	0.29%
Net Income (Continuing)	-14.72M	-8.67M	-14.33M	-11.8M	-3.57M	-4.62M	-5.09M	-5.15M	-4.83M	-3.46M
Discontinued Operations	4.56M	17.94M	0	0	265K	665K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-117.81	-221.70	-284.66	-127.68	-22.40	-23.65	-19.17	-15.18	-5.32	-2.79
EPS Growth %	0.09%	-0.88%	-0.28%	0.55%	0.82%	-0.06%	0.19%	0.21%	0.65%	0.48%
EPS (Basic)	-117.86	-221.70	-284.66	-127.68	-22.40	-23.65	-19.17	-15.18	-5.32	-2.79
Diluted Shares Outstanding	86.26K	46.93K	50.33K	92.4K	147.7K	199.6K	265.3K	339.4K	909K	1.24M
Basic Shares Outstanding	86.22K	46.93K	50.33K	92.4K	147.7K	199.6K	265.3K	339.4K	909K	1.24M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	12.89M	22.64M	16.25M	12.5M	12.38M	12.98M	16.43M	13.8M	12.55M	12.65M
Cash & Short-Term Investments	7.47M	17.46M	10.07M	3.69M	3.69M	4.22M	7.4M	3.82M	3.13M	5.37M
Cash Only	7.47M	17.46M	10.07M	3.69M	3.69M	4.22M	7.4M	3.82M	3.13M	5.37M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.51M	2.11M	1.54M	3.48M	3.97M	2.81M	2.41M	2.57M	5.99M	3.76M
Days Sales Outstanding	58.75	59.99	33.68	66.98	80.89	54.98	69.57	70.73	171.8	96.13
Inventory	1.64M	2.22M	2.87M	3.41M	2.19M	2.53M	2.66M	2.86M	2.72M	2.92M
Days Inventory Outstanding	89.06	113.27	111.87	123.32	81.59	76.51	112.56	118.61	124.21	120.59
Other Current Assets	811K	237K	239K	223K	271K	209K	218K	240K	367K	360K
Total Non-Current Assets+	915K	2.82M	2.95M	1.95M	2.18M	2M	2.42M	2.43M	2.19M	1.04M
Property, Plant & Equipment	850K	1.24M	1.14M	727K	1.33M	1.13M	879K	906K	651K	309K
Fixed Asset Turnover	11.02x	10.35x	14.66x	26.09x	13.50x	16.50x	14.37x	14.65x	19.56x	46.24x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	65K	1.58M	1.82M	1.23M	850K	875K	707K	578K	396K	147K
Total Assets+	13.8M	25.46M	19.21M	14.45M	14.56M	14.99M	18.84M	16.23M	14.74M	13.69M
Asset Turnover	0.68x	0.50x	0.87x	1.31x	1.23x	1.24x	0.67x	0.82x	0.86x	1.04x
Asset Growth %	-0.08%	0.84%	-0.25%	-0.25%	0.01%	0.03%	0.26%	-0.14%	-0.09%	-0.07%
Total Current Liabilities+	3.55M	3.29M	3.26M	3.59M	4.73M	4.08M	5.82M	3.72M	3.72M	4.1M
Accounts Payable	1.34M	1.25M	1.27M	1.25M	2.07M	1.77M	1.64M	841K	607K	953K
Days Payables Outstanding	72.61	64	49.67	45.4	76.94	53.49	69.36	34.9	27.73	39.42
Short-Term Debt	114K	123K	230K	322K	481K	596K	808K	431K	323K	220K
Deferred Revenue (Current)	574K	521K	206K	102K	273K	319K	1000K	160K	478K	641K
Other Current Liabilities	300K	0	589K	814K	0	367K	784K	566K	694K	487K
Current Ratio	3.63x	6.89x	4.98x	3.48x	2.62x	3.18x	2.82x	3.71x	3.37x	3.09x
Quick Ratio	3.17x	6.21x	4.11x	2.53x	2.16x	2.56x	2.37x	2.94x	2.64x	2.38x
Cash Conversion Cycle	75.2	109.26	95.88	144.9	85.54	77.99	112.77	154.44	268.28	177.3
Total Non-Current Liabilities+	112K	740K	619K	368K	4.21M	5.55M	4.33M	4.54M	4.88M	5.19M
Long-Term Debt	0	45K	32K	12K	0	1.31M	0	0	0	0
Capital Lease Obligations	0	168K	144K	0	235K	529K	309K	162K	87K	27K
Deferred Tax Liabilities	0	-168K	-144K	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	144K	0	3.73M	3.48M	3.84M	4.24M	4.71M	5.14M
Total Liabilities	3.66M	4.03M	3.88M	3.96M	8.94M	9.62M	10.15M	8.25M	8.6M	9.28M
Total Debt+	114K	410K	553K	475K	850K	2.67M	1.37M	849K	608K	305K
Net Debt	-7.36M	-17.05M	-9.51M	-3.21M	-2.84M	-1.54M	-6.03M	-2.97M	-2.52M	-5.07M
Debt / Equity	0.01x	0.02x	0.04x	0.05x	0.15x	0.50x	0.16x	0.11x	0.10x	0.07x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-4904.67x	-4324.67x	-354.73x	-341.15x	-461.88x	-287.42x	-588.70x	-	-	-
Total Equity+	10.14M	21.43M	15.33M	10.49M	5.62M	5.36M	8.7M	7.98M	6.14M	4.41M
Equity Growth %	-0.16%	1.11%	-0.28%	-0.32%	-0.46%	-0.05%	0.62%	-0.08%	-0.23%	-0.28%
Book Value per Share	117.56	456.64	304.50	113.52	38.08	26.87	32.78	23.50	6.75	3.55
Total Shareholders' Equity	10.14M	21.43M	15.33M	10.49M	5.62M	5.36M	8.7M	7.98M	6.14M	4.41M
Common Stock	2K	1K	1K	2K	2K	2K	2K	5K	2K	0
Retained Earnings	-152.38M	-143.1M	-157.44M	-169.24M	-175.33M	-179.28M	-184.36M	-189.51M	-194.35M	-197.81M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.85M	-4.18M	-3.98M	-4.35M	-5.61M	-4.58M	-4.31M	-3.42M	-2.72M	-4.38M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-8.75M	-8.17M	-12.44M	-11.72M	-4.59M	-3.38M	-4.25M	-6.15M	-2.4M	-88K
Operating CF Margin %	-0.93%	-0.64%	-0.75%	-0.62%	-0.26%	-0.18%	-0.34%	-0.46%	-0.19%	-0.01%
Operating CF Growth %	-0.31%	0.07%	-0.52%	0.06%	0.61%	0.26%	-0.26%	-0.45%	0.61%	0.96%
Net Income	-10.16M	9.27M	-14.33M	-11.8M	-3.31M	-3.95M	-5.09M	-5.15M	-4.83M	-3.46M
Depreciation & Amortization	244K	248K	490K	453K	312K	227K	186K	125K	176K	138K
Stock-Based Compensation	2.34M	2.15M	2.41M	1.64M	839K	371K	382K	669K	516K	224K
Deferred Taxes	0	-4.27M	651K	0	0	-1.41M	-829K	-37K	-109K	357K
Other Non-Cash Items	493K	-15.31M	90K	-741K	-773K	4K	-2.03M	106K	161K	174K
Working Capital Changes	-1.66M	-257K	-1.75M	-1.27M	-1.66M	1.38M	3.13M	-1.86M	1.69M	2.48M
Change in Receivables	-1.28M	34K	11K	-1.16M	-2.19M	2.61M	1.97M	62K	-230K	434K
Change in Inventory	-382K	-675K	-583K	-779K	323K	-65K	-100K	44K	184K	-388K
Change in Payables	429K	-58K	9K	5K	336K	-796K	-157K	-864K	-278K	416K
Cash from Investing+	4.19M	18.22M	-201K	-131K	3.64M	388K	-99K	-258K	-2K	-80K
Capital Expenditures	-345K	-394K	-187K	-100K	-206K	-179K	-137K	-269K	-17K	-80K
CapEx % of Revenue	0.04%	0.03%	0.01%	0.01%	0.01%	0.01%	0.01%	0.02%	0%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2K	-21K	-14K	-31K	1.15M	567K	38K	11K	15K	0
Cash from Financing+	6.04M	-32K	5.24M	5.49M	1.03M	3.31M	7.4M	2.49M	1.68M	3.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	14K	98K	52K	0	0	0	216K	-259K	373K	356K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.09M	-8.56M	-12.63M	-11.82M	-4.8M	-3.56M	-4.38M	-6.42M	-2.42M	-168K
FCF Margin %	-0.97%	-0.67%	-0.76%	-0.62%	-0.27%	-0.19%	-0.35%	-0.48%	-0.19%	-0.01%
FCF Growth %	-0.33%	0.06%	-0.47%	0.06%	0.59%	0.26%	-0.23%	-0.46%	0.62%	0.93%
FCF per Share	-105.40	-182.41	-250.85	-127.89	-32.48	-17.82	-16.53	-18.92	-2.66	-0.14
FCF Conversion (FCF/Net Income)	0.86x	-0.88x	0.87x	0.99x	1.39x	0.86x	0.84x	1.19x	0.50x	0.03x
Interest Paid	0	0	0	0	16K	12K	24K	0	0	11K
Taxes Paid	0	0	0	0	0	941K	767K	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-91.57%	58.75%	-77.96%	-91.4%	-41.06%	-71.9%	-72.35%	-61.78%	-68.51%	-65.55%
Return on Invested Capital (ROIC)	-251.09%	-271.61%	-208.81%	-129.03%	-110.21%	-78.37%	-136.15%	-89.33%	-81.78%	-188.07%
Gross Margin	28.26%	44.19%	43.88%	46.81%	45.3%	35.21%	31.62%	33.73%	37.26%	38.25%
Net Margin	-108.46%	72.31%	-86.01%	-62.19%	-18.45%	-21.2%	-40.28%	-38.81%	-37.97%	-24.2%
Debt / Equity	0.01x	0.02x	0.04x	0.05x	0.15x	0.50x	0.16x	0.11x	0.10x	0.07x
Interest Coverage	-4904.67x	-4324.67x	-354.73x	-341.15x	-461.88x	-287.42x	-588.70x	-	-	-
FCF Conversion	0.86x	-0.88x	0.87x	0.99x	1.39x	0.86x	0.84x	1.19x	0.50x	0.03x
Revenue Growth	-32.37%	36.89%	29.89%	13.88%	-5.49%	3.91%	-32.21%	5.1%	-4.05%	12.19%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Human Care	-	-	-	-	-	15.32M	-	-	10.11M	12.08M
Human Care Growth	-	-	-	-	-	-	-	-	-	19.48%
Animal Care	-	-	-	-	-	3.2M	-	-	2.2M	1.65M
Animal Care Growth	-	-	-	-	-	-	-	-	-	-24.97%
Service And Royalty	-	-	-	-	-	-	-	-	422K	556K
Service And Royalty Growth	-	-	-	-	-	-	-	-	-	31.75%
Shipping and Handling	-	-	-	55K	-	-	52K	42K	-	-
Shipping and Handling Growth	-	-	-	-	-	-	-	-19.23%	-	-
Service	-	-	995K	1.09M	-	-	349K	-	-	-
Service Growth	-	-	-	9.45%	-	-	-	-	-	-
Product	-	-	15.66M	-	15.69M	-	-	-	-	-
Product Growth	-	-	-	-	-	-	-	-	-	-
Human Skin Care	-	-	-	15.91M	-	-	-	-	-	-
Human Skin Care Growth	-	-	-	-	-	-	-	-	-	-
Animal Skin Care	-	-	-	1.97M	-	-	-	-	-	-
Animal Skin Care Growth	-	-	-	-	-	-	-	-	-	-
Product Revenues	-	2.69M	-	-	-	-	-	-	-	-
Product Revenues Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Latin America	4.88M	1.3M	-	-	-	-	-	-	-	-
Latin America Growth	-	-73.36%	-	-	-	-	-	-	-	-
United States	6.76M	-	-	-	-	-	-	-	-	-
United States Growth	-	-	-	-	-	-	-	-	-	-
Europe and Other	4.5M	-	-	-	-	-	-	-	-	-
Europe and Other Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Sonoma Pharmaceuticals, Inc. (SNOA) reported $16.9M in revenue for fiscal year 2025. This represents a 33% increase from $12.7M in 2012.

Sonoma Pharmaceuticals, Inc. (SNOA) grew revenue by 12.2% over the past year. This is steady growth.

Sonoma Pharmaceuticals, Inc. (SNOA) reported a net loss of $3.5M for fiscal year 2025.

Dividend & Returns

Sonoma Pharmaceuticals, Inc. (SNOA) has a return on equity (ROE) of -65.5%. Negative ROE indicates the company is unprofitable.

Sonoma Pharmaceuticals, Inc. (SNOA) had negative free cash flow of $1.4M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Sonoma Pharmaceuticals, Inc. (SNOA) 10-Year Financial Performance & Capital Metrics

SNOA • • Industrial / General

HealthcareSpecialty & Generic PharmaMedical Devices & Drug DeliveryDrug Delivery Systems

Revenue $14M +12.2%
EBITDA -$4M +21.1%
Net Income -$3M +28.5%
EPS (Diluted) -2.79 +47.6%
Gross Margin 38.25% +2.7%
EBITDA Margin -25% +29.6%
Operating Margin -25.97% +29.7%
Net Margin -24.2% +36.3%
ROE -65.55% +4.3%
ROIC -188.07% -130.0%
Debt/Equity 0.07 -30.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.9x book value
✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 36.5% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y0.31%

5Y-4.44%

3Y4.2%

TTM25.02%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM5.62%

EPS CAGR

10Y-

5Y-

3Y-

TTM52.15%

ROCE

10Y Avg-63.36%

5Y Avg-38.83%

3Y Avg-37.24%

Latest-35.99%

Peer Comparison

Drug Delivery Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
EMBCEmbecta Corp.	746.07M	12.60	7.78	-3.8%	8.77%		24.45%
SNOASonoma Pharmaceuticals, Inc.	5.56M	3.27	-1.17	12.19%	-20.54%	-91.87%		0.07
GELSGelteq Limited Ordinary Shares	13.28M	1.24		-100%	-27.42%	-26.77%		0.25

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	9.37M	12.82M	16.66M	18.97M	17.93M	18.63M	12.63M	13.27M	12.73M	14.29M
Revenue Growth %	-0.32%	0.37%	0.3%	0.14%	-0.05%	0.04%	-0.32%	0.05%	-0.04%	0.12%
Cost of Goods Sold+	6.72M	7.16M	9.35M	10.09M	9.81M	12.07M	8.63M	8.79M	7.99M	8.82M
COGS % of Revenue	0.72%	0.56%	0.56%	0.53%	0.55%	0.65%	0.68%	0.66%	0.63%	0.62%
Gross Profit+	2.65M	5.67M	7.31M	8.88M	8.12M	6.56M	3.99M	4.48M	4.75M	5.46M
Gross Margin %	0.28%	0.44%	0.44%	0.47%	0.45%	0.35%	0.32%	0.34%	0.37%	0.38%
Gross Profit Growth %	-0.64%	1.14%	0.29%	0.21%	-0.09%	-0.19%	-0.39%	0.12%	0.06%	0.15%
Operating Expenses+	17.36M	18.64M	21.5M	20.14M	15.51M	10.01M	9.88M	9.05M	9.45M	9.18M
OpEx % of Revenue	1.85%	1.45%	1.29%	1.06%	0.87%	0.54%	0.78%	0.68%	0.74%	0.64%
Selling, General & Admin	15.56M	17.07M	19.92M	18.62M	14.17M	9.45M	9.76M	8.84M	7.58M	7.36M
SG&A % of Revenue	1.66%	1.33%	1.2%	0.98%	0.79%	0.51%	0.77%	0.67%	0.59%	0.52%
Research & Development	1.81M	1.58M	1.57M	1.52M	1.34M	555K	125K	207K	1.87M	1.81M
R&D % of Revenue	0.19%	0.12%	0.09%	0.08%	0.07%	0.03%	0.01%	0.02%	0.15%	0.13%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-14.71M	-12.97M	-14.19M	-11.26M	-7.39M	-3.45M	-5.89M	-4.57M	-4.7M	-3.71M
Operating Margin %	-1.57%	-1.01%	-0.85%	-0.59%	-0.41%	-0.19%	-0.47%	-0.34%	-0.37%	-0.26%
Operating Income Growth %	-1.21%	0.12%	-0.09%	0.21%	0.34%	0.53%	-0.71%	0.22%	-0.03%	0.21%
EBITDA+	-14.47M	-12.73M	-13.7M	-10.8M	-7.08M	-3.22M	-5.7M	-4.45M	-4.53M	-3.57M
EBITDA Margin %	-1.54%	-0.99%	-0.82%	-0.57%	-0.39%	-0.17%	-0.45%	-0.33%	-0.36%	-0.25%
EBITDA Growth %	-1.26%	0.12%	-0.08%	0.21%	0.34%	0.54%	-0.77%	0.22%	-0.02%	0.21%
D&A (Non-Cash Add-back)	244K	248K	490K	453K	312K	227K	186K	125K	176K	138K
EBIT	-14.72M	-12.93M	-14.24M	-11.31M	-3.53M	-3.45M	-5.89M	-4.57M	-4.7M	-3.71M
Net Interest Income+	-1K	19K	218K	157K	34K	4K	-10K	16K	0	0
Interest Income	2K	22K	258K	190K	50K	16K	0	16K	0	0
Interest Expense	3K	3K	40K	33K	16K	12K	10K	0	0	0
Other Income/Expense	-10K	37K	-89K	-82K	3.85M	-453K	469K	-614K	-330K	803K
Pretax Income+	-14.72M	-12.94M	-14.28M	-11.34M	-3.54M	-3.9M	-5.42M	-5.18M	-5.03M	-2.91M
Pretax Margin %	-1.57%	-1.01%	-0.86%	-0.6%	-0.2%	-0.21%	-0.43%	-0.39%	-0.4%	-0.2%
Income Tax+	0	-4.27M	50K	458K	29K	713K	-332K	-33K	-196K	550K
Effective Tax Rate %	0.69%	-0.72%	1%	1.04%	0.93%	1.01%	0.94%	0.99%	0.96%	1.19%
Net Income+	-10.16M	9.27M	-14.33M	-11.8M	-3.31M	-3.95M	-5.09M	-5.15M	-4.83M	-3.46M
Net Margin %	-1.08%	0.72%	-0.86%	-0.62%	-0.18%	-0.21%	-0.4%	-0.39%	-0.38%	-0.24%
Net Income Growth %	-0.24%	1.91%	-2.54%	0.18%	0.72%	-0.19%	-0.29%	-0.01%	0.06%	0.29%
Net Income (Continuing)	-14.72M	-8.67M	-14.33M	-11.8M	-3.57M	-4.62M	-5.09M	-5.15M	-4.83M	-3.46M
Discontinued Operations	4.56M	17.94M	0	0	265K	665K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-117.81	-221.70	-284.66	-127.68	-22.40	-23.65	-19.17	-15.18	-5.32	-2.79
EPS Growth %	0.09%	-0.88%	-0.28%	0.55%	0.82%	-0.06%	0.19%	0.21%	0.65%	0.48%
EPS (Basic)	-117.86	-221.70	-284.66	-127.68	-22.40	-23.65	-19.17	-15.18	-5.32	-2.79
Diluted Shares Outstanding	86.26K	46.93K	50.33K	92.4K	147.7K	199.6K	265.3K	339.4K	909K	1.24M
Basic Shares Outstanding	86.22K	46.93K	50.33K	92.4K	147.7K	199.6K	265.3K	339.4K	909K	1.24M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	12.89M	22.64M	16.25M	12.5M	12.38M	12.98M	16.43M	13.8M	12.55M	12.65M
Cash & Short-Term Investments	7.47M	17.46M	10.07M	3.69M	3.69M	4.22M	7.4M	3.82M	3.13M	5.37M
Cash Only	7.47M	17.46M	10.07M	3.69M	3.69M	4.22M	7.4M	3.82M	3.13M	5.37M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.51M	2.11M	1.54M	3.48M	3.97M	2.81M	2.41M	2.57M	5.99M	3.76M
Days Sales Outstanding	58.75	59.99	33.68	66.98	80.89	54.98	69.57	70.73	171.8	96.13
Inventory	1.64M	2.22M	2.87M	3.41M	2.19M	2.53M	2.66M	2.86M	2.72M	2.92M
Days Inventory Outstanding	89.06	113.27	111.87	123.32	81.59	76.51	112.56	118.61	124.21	120.59
Other Current Assets	811K	237K	239K	223K	271K	209K	218K	240K	367K	360K
Total Non-Current Assets+	915K	2.82M	2.95M	1.95M	2.18M	2M	2.42M	2.43M	2.19M	1.04M
Property, Plant & Equipment	850K	1.24M	1.14M	727K	1.33M	1.13M	879K	906K	651K	309K
Fixed Asset Turnover	11.02x	10.35x	14.66x	26.09x	13.50x	16.50x	14.37x	14.65x	19.56x	46.24x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	65K	1.58M	1.82M	1.23M	850K	875K	707K	578K	396K	147K
Total Assets+	13.8M	25.46M	19.21M	14.45M	14.56M	14.99M	18.84M	16.23M	14.74M	13.69M
Asset Turnover	0.68x	0.50x	0.87x	1.31x	1.23x	1.24x	0.67x	0.82x	0.86x	1.04x
Asset Growth %	-0.08%	0.84%	-0.25%	-0.25%	0.01%	0.03%	0.26%	-0.14%	-0.09%	-0.07%
Total Current Liabilities+	3.55M	3.29M	3.26M	3.59M	4.73M	4.08M	5.82M	3.72M	3.72M	4.1M
Accounts Payable	1.34M	1.25M	1.27M	1.25M	2.07M	1.77M	1.64M	841K	607K	953K
Days Payables Outstanding	72.61	64	49.67	45.4	76.94	53.49	69.36	34.9	27.73	39.42
Short-Term Debt	114K	123K	230K	322K	481K	596K	808K	431K	323K	220K
Deferred Revenue (Current)	574K	521K	206K	102K	273K	319K	1000K	160K	478K	641K
Other Current Liabilities	300K	0	589K	814K	0	367K	784K	566K	694K	487K
Current Ratio	3.63x	6.89x	4.98x	3.48x	2.62x	3.18x	2.82x	3.71x	3.37x	3.09x
Quick Ratio	3.17x	6.21x	4.11x	2.53x	2.16x	2.56x	2.37x	2.94x	2.64x	2.38x
Cash Conversion Cycle	75.2	109.26	95.88	144.9	85.54	77.99	112.77	154.44	268.28	177.3
Total Non-Current Liabilities+	112K	740K	619K	368K	4.21M	5.55M	4.33M	4.54M	4.88M	5.19M
Long-Term Debt	0	45K	32K	12K	0	1.31M	0	0	0	0
Capital Lease Obligations	0	168K	144K	0	235K	529K	309K	162K	87K	27K
Deferred Tax Liabilities	0	-168K	-144K	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	144K	0	3.73M	3.48M	3.84M	4.24M	4.71M	5.14M
Total Liabilities	3.66M	4.03M	3.88M	3.96M	8.94M	9.62M	10.15M	8.25M	8.6M	9.28M
Total Debt+	114K	410K	553K	475K	850K	2.67M	1.37M	849K	608K	305K
Net Debt	-7.36M	-17.05M	-9.51M	-3.21M	-2.84M	-1.54M	-6.03M	-2.97M	-2.52M	-5.07M
Debt / Equity	0.01x	0.02x	0.04x	0.05x	0.15x	0.50x	0.16x	0.11x	0.10x	0.07x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-4904.67x	-4324.67x	-354.73x	-341.15x	-461.88x	-287.42x	-588.70x	-	-	-
Total Equity+	10.14M	21.43M	15.33M	10.49M	5.62M	5.36M	8.7M	7.98M	6.14M	4.41M
Equity Growth %	-0.16%	1.11%	-0.28%	-0.32%	-0.46%	-0.05%	0.62%	-0.08%	-0.23%	-0.28%
Book Value per Share	117.56	456.64	304.50	113.52	38.08	26.87	32.78	23.50	6.75	3.55
Total Shareholders' Equity	10.14M	21.43M	15.33M	10.49M	5.62M	5.36M	8.7M	7.98M	6.14M	4.41M
Common Stock	2K	1K	1K	2K	2K	2K	2K	5K	2K	0
Retained Earnings	-152.38M	-143.1M	-157.44M	-169.24M	-175.33M	-179.28M	-184.36M	-189.51M	-194.35M	-197.81M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.85M	-4.18M	-3.98M	-4.35M	-5.61M	-4.58M	-4.31M	-3.42M	-2.72M	-4.38M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-8.75M	-8.17M	-12.44M	-11.72M	-4.59M	-3.38M	-4.25M	-6.15M	-2.4M	-88K
Operating CF Margin %	-0.93%	-0.64%	-0.75%	-0.62%	-0.26%	-0.18%	-0.34%	-0.46%	-0.19%	-0.01%
Operating CF Growth %	-0.31%	0.07%	-0.52%	0.06%	0.61%	0.26%	-0.26%	-0.45%	0.61%	0.96%
Net Income	-10.16M	9.27M	-14.33M	-11.8M	-3.31M	-3.95M	-5.09M	-5.15M	-4.83M	-3.46M
Depreciation & Amortization	244K	248K	490K	453K	312K	227K	186K	125K	176K	138K
Stock-Based Compensation	2.34M	2.15M	2.41M	1.64M	839K	371K	382K	669K	516K	224K
Deferred Taxes	0	-4.27M	651K	0	0	-1.41M	-829K	-37K	-109K	357K
Other Non-Cash Items	493K	-15.31M	90K	-741K	-773K	4K	-2.03M	106K	161K	174K
Working Capital Changes	-1.66M	-257K	-1.75M	-1.27M	-1.66M	1.38M	3.13M	-1.86M	1.69M	2.48M
Change in Receivables	-1.28M	34K	11K	-1.16M	-2.19M	2.61M	1.97M	62K	-230K	434K
Change in Inventory	-382K	-675K	-583K	-779K	323K	-65K	-100K	44K	184K	-388K
Change in Payables	429K	-58K	9K	5K	336K	-796K	-157K	-864K	-278K	416K
Cash from Investing+	4.19M	18.22M	-201K	-131K	3.64M	388K	-99K	-258K	-2K	-80K
Capital Expenditures	-345K	-394K	-187K	-100K	-206K	-179K	-137K	-269K	-17K	-80K
CapEx % of Revenue	0.04%	0.03%	0.01%	0.01%	0.01%	0.01%	0.01%	0.02%	0%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2K	-21K	-14K	-31K	1.15M	567K	38K	11K	15K	0
Cash from Financing+	6.04M	-32K	5.24M	5.49M	1.03M	3.31M	7.4M	2.49M	1.68M	3.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	14K	98K	52K	0	0	0	216K	-259K	373K	356K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.09M	-8.56M	-12.63M	-11.82M	-4.8M	-3.56M	-4.38M	-6.42M	-2.42M	-168K
FCF Margin %	-0.97%	-0.67%	-0.76%	-0.62%	-0.27%	-0.19%	-0.35%	-0.48%	-0.19%	-0.01%
FCF Growth %	-0.33%	0.06%	-0.47%	0.06%	0.59%	0.26%	-0.23%	-0.46%	0.62%	0.93%
FCF per Share	-105.40	-182.41	-250.85	-127.89	-32.48	-17.82	-16.53	-18.92	-2.66	-0.14
FCF Conversion (FCF/Net Income)	0.86x	-0.88x	0.87x	0.99x	1.39x	0.86x	0.84x	1.19x	0.50x	0.03x
Interest Paid	0	0	0	0	16K	12K	24K	0	0	11K
Taxes Paid	0	0	0	0	0	941K	767K	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-91.57%	58.75%	-77.96%	-91.4%	-41.06%	-71.9%	-72.35%	-61.78%	-68.51%	-65.55%
Return on Invested Capital (ROIC)	-251.09%	-271.61%	-208.81%	-129.03%	-110.21%	-78.37%	-136.15%	-89.33%	-81.78%	-188.07%
Gross Margin	28.26%	44.19%	43.88%	46.81%	45.3%	35.21%	31.62%	33.73%	37.26%	38.25%
Net Margin	-108.46%	72.31%	-86.01%	-62.19%	-18.45%	-21.2%	-40.28%	-38.81%	-37.97%	-24.2%
Debt / Equity	0.01x	0.02x	0.04x	0.05x	0.15x	0.50x	0.16x	0.11x	0.10x	0.07x
Interest Coverage	-4904.67x	-4324.67x	-354.73x	-341.15x	-461.88x	-287.42x	-588.70x	-	-	-
FCF Conversion	0.86x	-0.88x	0.87x	0.99x	1.39x	0.86x	0.84x	1.19x	0.50x	0.03x
Revenue Growth	-32.37%	36.89%	29.89%	13.88%	-5.49%	3.91%	-32.21%	5.1%	-4.05%	12.19%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Human Care	-	-	-	-	-	15.32M	-	-	10.11M	12.08M
Human Care Growth	-	-	-	-	-	-	-	-	-	19.48%
Animal Care	-	-	-	-	-	3.2M	-	-	2.2M	1.65M
Animal Care Growth	-	-	-	-	-	-	-	-	-	-24.97%
Service And Royalty	-	-	-	-	-	-	-	-	422K	556K
Service And Royalty Growth	-	-	-	-	-	-	-	-	-	31.75%
Shipping and Handling	-	-	-	55K	-	-	52K	42K	-	-
Shipping and Handling Growth	-	-	-	-	-	-	-	-19.23%	-	-
Service	-	-	995K	1.09M	-	-	349K	-	-	-
Service Growth	-	-	-	9.45%	-	-	-	-	-	-
Product	-	-	15.66M	-	15.69M	-	-	-	-	-
Product Growth	-	-	-	-	-	-	-	-	-	-
Human Skin Care	-	-	-	15.91M	-	-	-	-	-	-
Human Skin Care Growth	-	-	-	-	-	-	-	-	-	-
Animal Skin Care	-	-	-	1.97M	-	-	-	-	-	-
Animal Skin Care Growth	-	-	-	-	-	-	-	-	-	-
Product Revenues	-	2.69M	-	-	-	-	-	-	-	-
Product Revenues Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Latin America	4.88M	1.3M	-	-	-	-	-	-	-	-
Latin America Growth	-	-73.36%	-	-	-	-	-	-	-	-
United States	6.76M	-	-	-	-	-	-	-	-	-
United States Growth	-	-	-	-	-	-	-	-	-	-
Europe and Other	4.5M	-	-	-	-	-	-	-	-	-
Europe and Other Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Sonoma Pharmaceuticals, Inc. (SNOA) reported $16.9M in revenue for fiscal year 2025. This represents a 33% increase from $12.7M in 2012.

Sonoma Pharmaceuticals, Inc. (SNOA) grew revenue by 12.2% over the past year. This is steady growth.

Sonoma Pharmaceuticals, Inc. (SNOA) reported a net loss of $3.5M for fiscal year 2025.

Dividend & Returns

Sonoma Pharmaceuticals, Inc. (SNOA) has a return on equity (ROE) of -65.5%. Negative ROE indicates the company is unprofitable.

Sonoma Pharmaceuticals, Inc. (SNOA) had negative free cash flow of $1.4M in fiscal year 2025, likely due to heavy capital investments.